59th annual conference of indian society of ... 2018_final.pdf savarkar marg, mahim, mumbai 400 016,
Post on 17-Mar-2020
Embed Size (px)
59th Annual Conference of Indian
Society of Gastroenterology
ISGCON 2018, KOCHI
Scientific Papers Presentation Schedule
59th ISGCON 2018
Lulu Bolgaty Convention Center
Subject/Category Abstract number Venue of
Nov 29, 2018 Plenary Session Abstract 1 to 6 Hall A 1100-1300 hrs Young Investigator Award
Abstract 7 to 12
Presidential Posters Abstract 13 to 64 ePoster presentation
ePosters will be
displayed from 9.00
till 18.00 hrs
Each ePanel will
display 10 papers
Judges will visit the
poster area between
1300-1400 hrs (Lunch
Esophagus Abstract 65 to 80
Stomach Abstract 81 to 96
Small Intestine Abstract 97 to112
Large Intestine Abstract 113 to145
Motility Disorders Abstract 146 to 154
Ped Gastroenterology Abstract 155 to 166
Epidemiology Abstract 167 to 169
Nov 30, 2018 Liver Abstract 170-306
Biliary Tract Abstract 307-322
Dec 1, 2018 Pancreas Abstract 323-361
Endoscopy Abstract 362-414
Nutrition Abstract 415-422
Case Reports Abstract 423-453
Guidelines for e-Poster Submission – ISGCON2018
Electronic Posters or e-Posters are similar to traditional paper/flex posters but displayed on
site on a 50” display. All accepted posters will be displayed on e-Poster stations.
Please note that, there will not be any physical posters at the ISGCON2018
The format/size of the posters should be in PowerPoint, Landscape, one slide only, which
should be in 16:9 ratio.By default, newer versions of PowerPoint use 16:9 ratio but for those
using older versions, make sure that you change the format from standard i.e. 4:3 to wide
screen 16:9 ratio by going to design and then to slide size in the tool bar.
You can also make posters in pdf or jpeg format as in traditional way in 70 cm(height) x 120
cm (width) in Landscape format. But, then these cannot be edited later if required. Please
email the soft copy of poster to the below mentioned email id.
To be of value, your poster should not be too cluttered. It should be set out in a clear and
logical manner, with reading matter reduced to an essential minimum. Lettering, including
figure legends, labelling, symbols & graphs etc, should be large enough to be legible when
viewed on a 50" screen. Ordinary type-face is NOT adequate. Drawings, diagrams, and
photos are extremely helpful and often necessary to display results and conclusions. Make
sure that your illustrations are easy to understand; do not overload any chart or drawing with
Recommended Font and Styles:
You should use dark text colours on a light background, or vice versa. Recommended fonts
are Times New Roman, Calibri, Verdana and Arial, as these are easy to read, and it is
possible that other fonts may have cross-operating system display issues.
Videos & animations are not allowed in your e-poster
You will be informed of your poster number as well as your computer assignment before the
meeting. However, when you arrive at the meeting, check to confirm the day, time and
monitor for your presentation, in case there have been last minute changes.
Please check the sample template and also see how this will be seen on a monitor. You can
use any template of your choice which fit your paper.
Please note the last date for submission/upload your e-poster is 24th November 2018. All
posters are required to be submitted much before time, but not later than Nov 24th, 2018. All
eposters will be loaded on an ePanel by the IT personnels.
No ePosters will be accepted at the venue. It must be sent earlier by mail.
ePosters will be displayed everyday from 9.00 till 18.00 hrs
There will be approximately 20 ePanels/ screens everyday and each ePanel will display 10
The list of Posters for a particular Screen and the Judge’s name will be displayed next to the
screen. Presentors of those 10 papers can present to the judge on that screen by turns.
Judges will visit the poster area between 1300-1400 hrs. Ensure your presence when the
judges are present.
Pl send ePoster to
You can mail to firstname.lastname@example.org
Call Mr Ranjeeth: +91 9902902288 or 8129134010
Plenary Session …
Young Investigator Award Session …
Presidential Posters …
Small Intestine …
Large Intestine …
Motility Disorders …
Pediatric Gastroenterology …
Biliary Tract …
Case Reports …
Author Index …
The Abstracts printed in this issue are as submitted by the Indian Society of
Gastroenterology. In no way, the Honorary Editor-in-Chief, Editorial Board Members, or
the printer/publishers are responsible for the results/findings and content of these Abstracts.
Indian - Society of Gastroenterology
Outcome of management protocol to reduce von Willebrand factor (vWF) in acute
hepatic dysfunction: Hepatotoxicity due to yellow phosphorus (rat killer) poisoning as a
Debasis Sardar, Nitty Mathews, Joy Mammen, S C Nair, Shibu Jacob, Mousumi Sen,
Vijayalekshmi, K A Balasubramanian, K Subramani, Lovely Thomas, K P P Abhilash,
Shankar Jhanwar, Ashish Goel, Uday Zachariah, Elwyn Eias, C E Eapen
Correspondence: C E Eapen – (email@example.com)
Gastroenterology and Hepatology, Christian Medical College, Vellore 632 004, India
Introduction: High vWF levels may predispose to platelet microthrombi and multi-organ
failure in phosphorus poisoning induced hepatotoxicity. We report outcome of vWF lowering
therapies: N–acetyl cysteine (NAC), fresh frozen plasma (FFP) infusions and plasma
exchange in these patients.
Method: In this retrospective analysis of prospectively collected data, patients were classified
to have uncomplicated acute hepatitis/UAH (deranged LFT, INR ≤1.5), acute liver
injury/ALI (deranged LFT, INR >1.5) and acute liver failure/ALF (ALI, hepatic
encephalopathy). ALF patients were advised liver transplantation, those not opting for
transplantation underwent plasma exchange and NAC infusion; ALI patients received
NAC±FFP infusions (plasma exchange, if worsening); UAH patients had oral NAC. Normal
plasma vWF antigen levels are 50% to 150%.
Results: Seventeen patients with hepatotoxicity due to phosphorus poisoning (December
2017 to July 2018), at presentation had UAH (one 19 year old male), ALI (13 patients, age 22
(15-35) years, median (range); 6 males)) or ALF (3 patients, age 25 (7-25) years; 1 male).
Baseline MELD scores were 11, 24 (12-38) and 36 (32-37); platelet counts were 1.59, 2
(1.05–3.51), and 1.63 (0.9–2.92), and plasma vWF antigen levels were 153%, 392 (146-
513)% and 448 (414- 555)% in UAH, ALI and ALF patients respectively. All 13 ALI
patients received NAC, 7 had FFP infusion, 3 had plasma exchange (2 (1-2) sessions). All 3
ALF patients had NAC and plasma exchange (5 (1-6) sessions). 11/13 (85%) ALI patients
survived, 2 progressed to ALF and died. Of 3 ALF patients, 2 (67%) survived. No patient
underwent liver transplantation. Of 5 patients meeting criteria for emergency liver
transplantation, 3 (60%) survived.
Conclusion: vWF lowering treatment in phosphorus poisoning induced hepatotoxicity
resulted in transplant free survival rates of 100% (UAH), 85% (ALI) and 67% (ALF).
Optimizing infliximab therapy using a Dashboard approach – An Indian experience
Mihika B Dave,1 Alpa Dherai,1 Devendra Desai,2 Diane Mould,3 Tester Ashavaid,1
Correspondence: Devendra Desai- (firstname.lastname@example.org) 1Department of Biochemistrty, 2Division of Gastroenterology, P D Hinduja Hospital, Veer
Savarkar Marg, Mahim, Mumbai 400 016, India, and 3Projections Research Inc.,
Phoenixville, Pennsylvania, USA
Introduction: Infliximab (IFX) pharmacokinetics is influenced by several variables. A few
patients fail to respond (primary non-responders) while there are others who form antibodies
and loose response with time (secondary non-responders). The complex multifactorial
relationship between covariates and IFX distribution limits a direct correlation between dose